Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2023 Aug 24:63:102172.
doi: 10.1016/j.eclinm.2023.102172. eCollection 2023 Sep.

Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

Jie Wang  1   2 , Hongyu Chen  3 , Zihuan Tang  3 , Jinquan Zhang  4 , Yuanwei Xu  1 , Ke Wan  5 , Kifah Hussain  6 , Georgios V Gkoutos  2   7   8   9 , Yuchi Han  10 , Yucheng Chen  1   11
Affiliations

Tafamidis treatment in patients with transthyretin amyloid cardiomyopathy: a systematic review and meta-analysis

Jie Wang et al. EClinicalMedicine. .

Abstract

Background: Previous studies have reported that tafamidis treatment was associated with better outcomes in patients with transthyretin amyloid cardiomyopathy (ATTR-CM) compared with those without tafamidis treatment. Therefore, we aimed to systematically assess the association of tafamidis treatment with outcomes in patients with ATTR-CM.

Methods: The protocol for this systematic review and meta-analysis was registered in the PROSPERO (CRD42022381985). Pubmed, Ovid Embase, Scopus, Cochrane Library, and Web of Science were interrogated to identify studies that evaluated the impact of tafamidis on prognosis in ATTR-CM, from January 1, 2000 to June 1, 2023. A random-effects model was used to determine the pooled risk ratio (RR) for the adverse endpoints. In addition, the main outcomes included all-cause death or heart transplantation, the composite endpoints included all-cause death, heart transplantation, cardiac-assist device implantation, heart failure exacerbations, and hospitalization.

Findings: Fifteen studies comprising 2765 patients (mean age 75.9 ± 9.3 years; 83.7% male) with a mean follow-up duration of 18.7 ± 17.1 months were included in the meta-analysis. There was a decrease in left ventricular ejection fraction (LVEF) (standard mean differences (SMD: -0.17; 95% confidence interval (CI), -0.31 to -0.03; P = 0.02) but were no significant differences in intraventricular septum (IVS) thickness or global longitudinal strain (GLS) after tafamidis treatment. However, subgroup analysis showed no significant deterioration in LVEF in the patients with wild-type ATTR after tafamidis treatment (SMD: -0.11; 95% CI, -0.34 to 0.12, P = 0.34). In addition, the group with tafamidis treatment had a decreased risk for all-cause death or heart transplantation compared to patients without treatment (the pooled RR, 0.44; 95% CI, 0.31-0.65; P < 0.01). Subgroup analysis showed that there was no significant difference of tafamidis on the outcomes in patients with wild-type or hereditary ATTR (RR, 0.44; 95% CI, 0.27-0.73 versus 0.21, 95% CI, 0.11-0.40, P = 0.08). Furthermore, tafamidis treatment was associated with a lower risk of the composite endpoint (RR, 0.57; 95% CI, 0.42-0.77; P < 0.01).

Interpretation: Our findings suggested that there was no significant deterioration in LVEF in the patients with wild-type ATTR after tafamidis treatment. In addition, tafamidis treatment was associated with a low risk of all-cause death and adverse cardiovascular events.

Funding: This work was supported by grants from the Natural Science Foundation of Sichuan Province [Grant Number: 23NSFSC4589] and the National Natural Science Foundation of China [Grant Number: 82202248].

Keywords: ATTR; Prognosis; Tafamidis; Transthyretin amyloid cardiomyopathy.

PubMed Disclaimer

Conflict of interest statement

All authors declare no competing interests.

Figures

Fig. 1
Fig. 1
Flowchart for included studies for themeta-analysis.
Fig. 2
Fig. 2
Pooled RR of tafamidis treatment for death or heart transplantation. The pooled RR for the all-cause death or heart transplantation (A) in patients with ATTR-CM and the subgroup analysis by types of ATTR (B). ATTR-CM = transthyretin amyloid cardiomyopathy; No. = number; RR = risk ratio.
Fig. 3
Fig. 3
Pooled RR of tafamidis treatment for the composite endpoint. The pooled RR for the composite endpoint (A) in patients with ATTR-CM and the subgroup analysis by types of ATTR (B). ATTR-CM = transthyretin amyloid cardiomyopathy; No. = number; RR = risk ratio.
Fig. 4
Fig. 4
Pooled SMD of tafamidis treatment for changes in LVEF, IVS, and GLS in patients with ATTR-CM. The pooled SMD represented the changes from baseline to follow-up after tafamidis treatment. ATTR-CM = transthyretin amyloid cardiomyopathy; SMD = standard mean difference; LVEF = left ventricular ejection fraction; IVS = intraventricular septum; GLS = global longitudinal strain.
Fig. 5
Fig. 5
Subgroup analysis of tafamidis treatment for changes in LVEF, IVS, and GLS in patients with wtATTR and hATTR. ATTR-CM = transthyretin amyloid cardiomyopathy; wtATTR = wild-type ATTR; hATTR = hereditary ATTR; SMD = standard mean difference; LVEF = left ventricular ejection fraction; IVS = intraventricular septum; GLS = global longitudinal strain.
See this image and copyright information in PMC

References

    1. Lane T., Fontana M., Martinez-Naharro A., et al. Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation. 2019;140(1):16–26. - PubMed
    1. Castaño A., Narotsky D.L., Hamid N., et al. Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement. Eur Heart J. 2017;38(38):2879–2887. - PMC - PubMed
    1. González-López E., Gallego-Delgado M., Guzzo-Merello G., et al. Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J. 2015;36(38):2585–2594. - PubMed
    1. Marques N., Azevedo O., Almeida A.R., et al. Specific therapy for transthyretin cardiac amyloidosis: a systematic literature review and evidence-based recommendations. J Am Heart Assoc. 2020;9(19) - PMC - PubMed
    1. Bulawa C.E., Connelly S., Devit M., et al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci U S A. 2012;109(24):9629–9634. - PMC - PubMed